|
Market Closed -
Nasdaq
16:00:00 2026-09-17 EDT
|
5-day change | 1st Jan Change | ||
| 5.280 USD | -2.40% |
|
-13.01% | +162.69% |
| 09-11 | HEALTH ROUNDS-Experimental eye drops ease night vision problems for drivers | RE |
| 09-10 | Wedbush Raises Price Target on Opus Genetics to $13 From $10, Keeps Outperform Rating | MT |
Company Valuation: Opus Genetics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 64.53 | 73.45 | 68.14 | 37.57 | 138.6 | 439.3 | - | - |
| Change | - | 13.82% | -7.23% | -44.87% | 268.99% | 216.9% | - | - |
| Enterprise Value (EV) | 64.53 | 73.45 | 68.14 | 37.57 | 138.6 | 439.3 | 439.3 | 439.3 |
| Change | - | 13.82% | -7.23% | -44.87% | 268.99% | 216.9% | 0% | 0% |
| P/E | -0.98x | 4.06x | -6.54x | -0.55x | -2.51x | -5.39x | -7.46x | -13.4x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0x | 0x | -0x | 0x | -0.2x | 0.3x | 0.3x |
| Capitalization / Revenue | 110x | 1.84x | 3.58x | 3.42x | 9.76x | 33.5x | 32.3x | 10x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 33.5x | 32.3x | 10x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | 0x | -0x | -0x | -0x | -7.73x | -6.62x | -8.57x |
| EV / FCF | -0x | - | -0x | -0x | -0x | -8.66x | -7.53x | -76.7x |
| FCF Yield | -30% | - | -1.63% | -68.1% | -25.4% | -11.6% | -13.3% | -1.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.82 | 0.87 | -0.46 | -2.15 | -0.8 | -0.98 | -0.7082 | -0.395 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 0.589 | 39.85 | 19.05 | 10.99 | 14.2 | 13.11 | 13.59 | 43.9 |
| EBITDA | -20.79 | - | - | - | - | - | - | - |
| EBIT 1 | -22.7 | 18.23 | -10.56 | -62.07 | -38.6 | -56.8 | -66.33 | -51.24 |
| Net income 1 | -56.69 | 17.89 | -9.986 | -57.53 | -49.59 | -91.93 | -68.94 | -52.16 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 3.730 | 3.530 | 3.010 | 1.190 | 2.010 | 5.280 | 5.280 | 5.280 |
| Nbr of stocks (in thousands) | 17,300 | 20,807 | 22,638 | 31,568 | 68,964 | 83,196 | - | - |
| Announcement Date | 3/24/22 | 3/30/23 | 3/8/24 | 3/31/25 | 3/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.52x | - | - | - | 450M | |
| 32.35x | 11.76x | 23.85x | 0.61% | 1,014B | |
| 29.73x | 6.61x | 18.52x | 2.01% | 644B | |
| 33.2x | 7.77x | 16.07x | 2.61% | 464B | |
| 19.64x | 4.8x | 11.88x | 2.76% | 354B | |
| 19.71x | 5.15x | 12.77x | 3.12% | 265B | |
| 20.89x | 4.31x | 12.32x | 2.04% | 253B | |
| 23.89x | 6.29x | 11.2x | 2.68% | 203B | |
| 12.12x | 4.42x | 9.24x | 4.14% | 186B | |
| -44.67x | 6.51x | 25.43x | 2.23% | 183B | |
| Average | 14.13x | 6.40x | 15.70x | 2.47% | 356.72B | |
| Weighted average by Cap. | 23.48x | 7.64x | 17.64x | 2.01% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IRD Stock
- Valuation Opus Genetics, Inc.
Select your edition
All financial news and data tailored to specific country editions
